Calls
1
u/Secure-Chipmunk6112
Reddit r/biotech_stocks
Win Rate
100.0%
return
+6.9%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 11
$1.31
+6.9%
InMed Pharmaceuticals is set to become Mentari Therapeutics via reverse merger, trading as MTRI on Nasdaq, as the 8th company spun out of the Paragon Therapeutics ecosystem. The author argues Paragon operates as a repeatable 'biotech factory' that develops antibody programs and spins them into independent biotechs, with Apogee acquired by AbbVie and Spyre and Korsana as prior examples. Mentari's pipeline targets migraine prevention with MT-001 (anti-PACAP antibody) and MT-002 (bispecific CGRP x PACAP antibody), with ~$290M financing and catalysts of MT-002 Phase 1 in 2027 and MT-001 Phase 2a/PoC in 2028. If clinical data is compelling, Mentari could become an acquisition target for Big Pharma, though the author flags significant early-stage clinical and development risk.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Secure-Chipmunk6112 has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: INM.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
